SM
ORKA

Sabby Management’s Oruka Therapeutics ORKA Stock Holding History

Sabby Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-463
Closed -$138K – 187
2017
Q4 		$138K Hold
463
– – 0.01% 129
2017
Q3 		$110K Buy
+463
New +$165K 0.01% 141
2015
Q2 		– Sell
-93
Closed -$112K – 363
2015
Q1 		$112K Buy
+93
New +$109K ﹤0.01% 272
2013
Q3 		– Sell
-654
Closed -$1.28M – 227
2013
Q2 		$1.28M Buy
+654
New +$2M 0.09% 107

Other funds holding ORKA

TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACP
Aveo Capital Partners Englewood, Colorado $601M AUM 5.92% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Sabby Management's ORKA Position: Q1 2018 in Review

Sabby Management sold out of Oruka Therapeutics (ORKA) in Q1 2018, closing a stake of 463 shares — an estimated $138K sold.

Sabby Management first reported a position in ORKA in Q2 2013 and held it in 4 quarters. The position peaked at $1.28M in Q2 2013. 16 funds tracked by Wall St. Rank hold ORKA as of Q1 2018.

  • Sabby Management reported no remaining Oruka Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Sabby Management sold 463 Oruka Therapeutics shares in Q1 2018, an estimated $138K.
  • Sabby Management first reported a position in Oruka Therapeutics in Q2 2013 and held it in 4 quarters.
  • Sabby Management's Oruka Therapeutics position peaked at $1.28M in Q2 2013.
  • 16 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2018.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.